3.86
0.40 (11.56%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Anavex Life Sciences Corp. | 看跌 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 3.0 |
| 技术平均移动指标 | -1.5 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.50 |
|
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 3.33% |
| 机构持股比例 | 37.67% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Two Sigma Investments, Lp | 30 Sep 2025 | 1,036,954 |
| Nwam Llc | 30 Sep 2025 | 874,283 |
| Two Sigma Advisers, Lp | 30 Sep 2025 | 758,500 |
| Lpl Financial Llc | 30 Sep 2025 | 534,319 |
| Private Advisor Group, Llc | 30 Sep 2025 | 455,125 |
| Summit Financial, Llc | 30 Sep 2025 | 444,271 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 24.00 (D. Boral Capital, 521.76%) | 购买 |
| 中 | 22.00 (469.95%) | |
| 低 | 20.00 (HC Wainwright & Co., 418.14%) | 购买 |
| 平均值 | 22.00 (469.95%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 3.73 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 26 Nov 2025 | 24.00 (521.76%) | 购买 | 3.86 |
| 14 Nov 2025 | 24.00 (521.76%) | 购买 | 3.65 | |
| HC Wainwright & Co. | 19 Nov 2025 | 20.00 (418.13%) | 购买 | 3.60 |
| 07 Oct 2025 | 42.00 (988.08%) | 购买 | 9.78 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合